arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Envoy Medical, Inc.

COCH

$0.68 ▼ -0.02 (-3.07%) at close

6 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

Envoy Medical, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $15.8M

Dividend Yield —

Revenue Growth 7.1% ↗

Op. Margin —

ROIC 144.7% ↗

FCF / Share $-0.79 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$241.00K

↑ +7.1% —

Net Income Profit after all expenses

$-23.76M

↓ -14.2% —

FCF / Share Free cash flow per share

$-0.79

↑ +21.6% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

100

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	7.1% Fair ↑ Fair Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-11%)	-28.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-460%)	33.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+317%)	—	—	—
EPS Growth YoY (%)	17.4% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	37.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-51.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-14.2% Weak ↑ Weak Improving Year-over-year change in net income	30.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-87.8% Weak Weak Year-over-year change in net income	-6227.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	21.6% Good ↑ Good Improving Year-over-year change in free cash flow	29.0% Excellent Excellent Year-over-year change in free cash flow	-59.2% Weak Weak Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	0.6% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	12.88x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	144.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	80.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	823.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	19.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	11.2% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-260.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-166.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-240.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-340.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-1.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	195.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1203%)	110.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+636%)	—	44.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+193%)	0.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-95%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	-14.01x Weak Weak Operating income divided by interest expense Optimal: > 5x	-23.60x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	—	—	$-4.22M	$-183.00K	$-149.84K	$-25.00K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.01	$0.01	$0.03	$0.02	—	—
Basic EPS, GAAP (USD)	$-1.23	$-1.49	$-2.38	$-1.57	—	—
Free Cash Flow per Share (USD)	$-0.79	$-1.01	$-1.42	$-0.89	—	—
Book Value per Share (USD)	$-0.52	$-1.00	$-0.09	$-3.58	—	—
Tangible Book Value per Share (USD)	$-0.52	$-1.00	$-0.09	$-3.58	—	—
Basic Weighted Avg Shares (shares)	23.26M	18.79M	12.55M	10.12M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$-5.28M	$1.36M	$189.00K	$-871.00K	$-1.82M	$-70.69K
Total Equity (USD)	$-12.16M	$-18.84M	$-1.76M	$-36.20M	$-36.71M	$24.30K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$241.00K	$225.00K	$316.00K	$237.00K	—	—
Depreciation Expense (USD)	$302.00K	$173.00K	$133.00K	$75.00K	—	—
Net Income, GAAP (USD)	$-23.76M	$-20.80M	$-29.91M	$-15.92M	$-251.63K	—
Operating Cash Flow (USD)	$-18.20M	$-17.95M	$-17.65M	$-8.80M	$-3.24M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

Envoy Medical, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare COCH with peers